The ribosome inactivating proteins (RIPs) from plants possess RNA N- glycosidase activity that depurinates the major rRNA, thus damaging ribosomes in an irreversible manner and arresting protein synthesis. RIPs are presently classified as rRNA N-glycosidase in the enzyme nomenclature (EC 18.104.22.168) and do exhibit other enzymatic activities such as ribonuclease and deoxyribonuclease activities. RIPs have been shown to manifest abortifacient, anti-tumor, anti-viral and anti-microbial activities. RIPs are detected in some medicinal plants but the yields are insufficient to warrant their availability to conduct clinical trials for therapeutic application. Here, we describe an approach based on “bioprocess development” that may enhance the yield of RIPs and eventually their availability for exploiting their therapeutic potential.
Field of Research
100302 Bioprocessing, Bioproduction and Bioproducts
Socio Economic Objective
860105 Nutraceuticals and Functional Foods
HERDC Research category
E2.1 Full written paper - non-refereed / Abstract reviewed
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact firstname.lastname@example.org.